Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.

Receiving the FDA’s clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

Researchers at McMaster University have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine.

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label, dose ...